Fig. 2: LA-Agonist has the same effect on body weight as muGIPR-Ab.

a–k DIO mice dosed with vehicle, liraglutide, LA-Agonist, muGIPR-Ab, LA-Agonist + liraglutide, or muGIPR-Ab + liraglutide for 21 days. a Body weight change from day 1. On day 21, Vehicle vs. Liraglutide ****p ≤ 0.0001, Vehicle vs. LA-Agonist p = 0.077, Vehicle vs. muGIPR-Ab **p = 0.0082, Vehicle vs. Liraglutide + LA-Agonist ****p ≤ 0.0001, and Vehicle vs. Liraglutide + muGIPR-Ab ****p ≤ 0.0001. b 3-day average food intake measured over time. On days 1–3, **p = 0.0089 and ****p ≤ 0.0001; on days 7–9, ***p = 0.0020 and ****p ≤ 0.0001; and on days 13–15, **p = 0.0031 and ****p ≤ 0.0001. c Total fat mass measured by MRI on day 18. **p = 0.0032 and ****p ≤ 0.0001. Tissue weights collected at necropsy d scWAT, e eWAT, and f liver weights. d **p = 0.0044 and *p = 0.016, e *p = 0.040 and ****p ≤ 0.0001; and f Vehicle vs. Liraglutide *p = 0.017, Vehicle vs. LA-Agonist + Liraglutide *p = 0.021, and **p = 0.0059. Four-hour fasted plasma adipokines (g) leptin, (h) resistin, and (i) adiponectin collected on day 21. g *p = 0.018, **p = 0.0071, ***p = 0.0001, and ****p ≤ 0.0001; h ***p = 0.0001 and ****p ≤ 0.0001; and i *p = 0.027. j Plasma insulin and k blood glucose concentrations were measured before and after IP injections of DA-GIP and glucose. j At 15 min, Vehicle vs. Liraglutide *p = 0.026, Vehicle vs. muGIPR-Ab *p = 0.024, Vehicle vs. LA-Agonist + Liraglutide **p = 0.0022, Vehicle vs. muGIPR-Ab + Liraglutide **p = 0.0064, and LA-Agonist vs. muGIPR-Ab **p = 0.0043. k At 80 min, Vehicle vs. LA-Agonist ***p = 0.0009, Vehicle vs. LA-Agonist + Liraglutide ***p = 0.0001, and Vehicle vs. muGIPR-Ab + Liraglutide ***p = 0.0004. a–k n = 8 mice/group; a, j, k two-way repeated measures ANOVA with Tukey’s multiple comparisons test; b two-way ANOVA with Tukey’s multiple comparisons test; c–i one-way ANOVA with Sidak’s multiple comparisons test. Data are presented as mean values ± SEM.